US House Passes Bipartisan Bill to Reauthorize FDA's Rare Pediatric Disease Priority Review Voucher Program
核心洞察
The US House of Representatives unanimously passed the Mikaela Naylon Give Kids a Chance Act, reauthorizing the FDA's rare pediatric disease priority review voucher program that expired in December 2024.
The legislation combines regulatory frameworks to accelerate therapy access for children with rare diseases and certain cancers, with priority review vouchers currently valued at approximately $150 million.
Industry organizations and patient advocacy groups strongly support the bill, emphasizing its critical role in incentivizing pharmaceutical companies to develop treatments for rare pediatric conditions.
The US House of Representatives has unanimously passed the Mikaela Naylon Give Kids a Chance Act, a bipartisan bill that reauthorizes the FDA's rare pediatric disease (RPD) priority review voucher (PRV) program after it expired in December 2024. The legislation represents a critical step forward for children battling rare diseases and certain cancers who need faster access to life-saving therapies.
Legislative Framework and Objectives
First introduced by Republican congressman Michael McCaul in February 2025, the bill combines two initiatives: the original Give Kids a Chance Act and the Creating Hope Reauthorisation Act. The comprehensive legislation aims to spur drug development for pediatric rare diseases, improve patient outcomes, and address gaps in pediatric drug research.
The bill is named after Mikaela Naylon, a young woman who advocated for its passage before dying this year from complications related to osteosarcoma (搜索), a rare type of bone cancer. McCaul emphasized the legislation's significance, stating: "I've met with countless cancer patients and advocates who have asked me for one thing: to give kids their best chance of beating cancer. Today, the House of Representatives shined a beacon of hope for those children and their families by unanimously passing the Mikaela Naylon Give Kids A Chance Act."
Priority Review Voucher Program Impact
The centerpiece of the legislation is the reauthorization of the RPD PRV program, originally created under McCaul's Creating Hope Act. This pathway incentivizes pharmaceutical companies to develop drugs for rare pediatric diseases by offering priority review vouchers upon FDA approval. These vouchers can either reduce review time by four months for another product or be sold for substantial financial returns.
Currently, priority review vouchers command approximately $150 million in the marketplace. Recent transactions demonstrate their significant value: Bavarian Nordic secured $160 million from selling a voucher in June 2024, while Ipsen received $158 million in August 2024 for a PRV awarded following approval of the rare disease drug Sohonos. Abeona Therapeutics sold a PRV for $155 million in May 2024, just two weeks after receiving it for their gene therapy Zevaskyn (搜索).
Industry and Advocacy Support
The bill's passage has garnered widespread support from industry organizations and patient advocacy groups. Stacey Frisk, executive director of the Rare Disease Company Coalition (搜索), called the House passage "a massive step forward for the rare disease community," urging the Senate to prioritize the legislation to ensure the PRV program is reinstated quickly.
The Biotechnology Innovation Organization (搜索) (BIO) praised the unanimous House passage as "a victory for children and families living with rare diseases," highlighting the reauthorization of the Pediatric Priority Review Voucher programme as a key component. The EveryLife Foundation for Rare Diseases (搜索) noted that the milestone resulted from "community-driven advocacy and dedication from rare disease patients, families, organisations, and others who shared their stories."
Biotech Industry Perspective
SynaptixBio (搜索), which holds two Rare Paediatric Disease Designations from the FDA for H-ABC (搜索) and Isolated Hypomyelination (搜索), exemplifies the program's importance for smaller biotechnology companies. CEO Dan Williams emphasized the PRV scheme's role as "a vital lifeline for small biotechs developing rare diseases therapies," noting that developing therapies for rare diseases is "a moral imperative" affecting millions worldwide.
Williams highlighted the structural dynamics of rare disease drug development, explaining that smaller biotechs typically work on rare disease therapies while larger pharmaceutical companies focus on mass-market drugs. However, he noted the potential synergy where "Big Pharma doesn't face the high investment risk of developing a rare disease drug, and the smaller biotech has a natural target for selling its PRV."
Next Steps and Timeline
The bill now moves to the Senate for consideration. If passed there, it will be sent to President Trump for final approval. The urgency of reauthorization stems from the program's expiration in December 2024 due to political and congressional delays, leaving a critical gap in incentives for rare pediatric disease drug development.
The PRV program's sunset clause requires periodic reauthorization, and its lapse in December 2024 occurred amid debates over effectiveness and concerns about high PRV prices. Patient advocacy groups and pharmaceutical industry bodies have consistently called for reauthorization, emphasizing the framework's importance in bringing innovative therapies to market for underserved pediatric populations.